The 2025 Terpene-Enhanced CBD Trial

A 2025 randomized controlled trial tested 300mg of CBD combined with eight terpenes on 125 people with diagnosed insomnia. Participants took the formula at least four days a week for four weeks. Researchers measured sleep stages using wrist-worn trackers.

The CBD-terpene mix increased slow-wave and REM sleep by 1.3% compared to placebo. Some participants gained up to 48 minutes of these restorative sleep stages per night. Total sleep time stayed the same. Heart rate measurements showed no changes, and no one reported adverse events.

The study excluded people with other sleep disorders and THC users. This isolation helped researchers track CBD effects without confounding variables.

Cognitive Function Studies Show Mixed Results

A 2024 pilot trial gave 15 people 150mg sublingual CBD nightly for two weeks. Another 15 received a placebo. Researchers tested memory, attention, reasoning, and executive function using the CogPro system.

CBD did not affect cognitive performance. All test scores matched placebo group results. Participants taking CBD reported feeling calmer and clearer-headed. They also experienced more dry mouth than the placebo group.

The trial enrolled adults with primary insomnia only. People with psychiatric conditions or substance use disorders could not participate. These strict criteria limit how findings apply to broader populations.

Alternative Cannabinoid Forms and Research Gaps

Researchers continue testing cannabinoid preparations beyond standard CBD isolates. Some studies examine CBD oils, capsules, and tinctures. Others investigate cannabinol (CBN), cannabigerol (CBG), and products with delta 8 THC. Each compound acts on different receptors and pathways.

CBN shows promise for reducing sleep onset in preliminary trials. Delta 8 THC products remain less studied than CBD formulations in clinical sleep research.

Current trials focus mainly on oral CBD at 150-300mg doses. Few studies compare different cannabinoids head-to-head for insomnia. Data on long-term use beyond 4-8

weeks is lacking. Most trials exclude participants taking other sleep medications or those with comorbid conditions, which limits real-world applicability.

Failed Trials and Null Findings

Multiple CBD studies found no sleep benefits. Several trials using 200-300mg CBD showed no improvement over placebo. One study combining 10mg THC with 200mg CBD resulted in participants sleeping 25 minutes less per night than those on a placebo.

Company-sponsored trials using under 100mg CBD doses report consistent failures. These studies measured insomnia scales, sleep latency, and quality ratings. None showed meaningful improvements. Some companies chose not to publish their null results.

Patient Response Varies by Baseline Characteristics

People with low baseline slow-wave and REM sleep respond better to CBD than those with normal sleep patterns. Day sleepers showed stronger responses than night sleepers in the 2025 trial. Age also affects outcomes, though researchers need more data to establish patterns.

Anxiety may influence CBD effectiveness for sleep. An ongoing multi-site trial tracks both anxiety and sleep in adults with moderate to severe anxiety scores. This study may clarify if CBD helps sleep through anxiety reduction rather than direct sleep effects.

Previous sedative use predicts CBD response. People who stopped benzodiazepines or Z-drugs due to side effects sometimes report better results with CBD. Those who never used prescription sleep aids show more variable responses.

Formulation Makes a Difference

CBD isolate performs differently from broad-spectrum formulations. Adding terpenes like linalool and myrcene may enhance sedative effects through GABA receptor modulation. The 2025 trial’s positive results came from a multi-terpene formula, not pure CBD.

Delivery method also affects outcomes. Oral capsules take longer to work than sublingual drops. Inhaled CBD produces rapid effects but creates dosing problems in research settings. Most trials use oral or sublingual routes for consistency.

Dose timing matters. Taking CBD 30-60 minutes before bed differs from afternoon dosing. Some protocols split doses throughout the day, while others use a single nighttime administration. These variations complicate comparisons across studies.

Safety Profile Remains Favorable

Short-term CBD use causes mild side effects. Dry mouth occurs most frequently. Some people report loose stools or mild sedation, but these effects rarely cause trial dropouts.

CBD avoids issues common with prescription sleep drugs. Benzodiazepines suppress REM sleep and increase fall risk. Z-drugs cause next-day grogginess and dependency. CBD shows no dependency signals in current research.

Blood work from safety monitoring reveals minimal changes. Liver enzymes stay normal at typical doses. Drug interaction potential exists but appears lower than that of many sleep medications.

Comparison to Standard Treatments Falls Short

CBD produces smaller effects than approved insomnia medications. Zolpidem reduces sleep onset by similar minutes but works more consistently. Melatonin shows comparable modest benefits with better predictability.

Cost considerations favor conventional treatments. Insurance covers prescription sleep aids. CBD remains an out-of-pocket expense, and the price per month exceeds most generic sleep medications.

What Research Still Needs to Answer

Long-term safety data beyond eight weeks remains absent. Researchers have not studied CBD withdrawal effects systematically. Tolerance development needs investigation.

Optimal dosing protocols lack consensus. Some experts suggest weight-based dosing, while others recommend starting low and titrating up. No standardized approach exists.

Drug interactions require more study. CBD affects cytochrome P450 enzymes, which could alter levels of other medications. Current trials exclude participants on multiple drugs, limiting real-world applicability.

Current Expert Positions

Sleep specialists do not recommend CBD as first-line insomnia treatment. The evidence base remains too weak for clinical guidelines. Some doctors suggest CBD for patients who fail standard treatments.

Regulatory uncertainty complicates medical recommendations. CBD products lack FDA approval for insomnia. Quality control varies between manufacturers, making physicians hesitant to recommend unregulated products.

Research funding priorities favor traditional pharmaceuticals. CBD studies receive less support than conventional drug trials. This funding gap slows evidence accumulation. Academic centers conduct most CBD research with limited budgets.

—

Conclusion

Research on CBD and insomnia is promising but remains inconclusive. While certain trials highlight improvements in sleep stages—especially with terpene-enhanced formulations—many studies show inconsistent or null results. Patient variability, dosing strategies, and delivery methods all influence outcomes. Safety data is favorable, but CBD still falls short compared to standard treatments in reliability and cost-effectiveness. For now, CBD should be considered a complementary option rather than a primary insomnia treatment. Larger trials, regulatory clarity, and long-term safety data will determine its true role in sleep medicine.